Literature DB >> 22426129

Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice.

Christian Rask-Madsen1, Erica Buonomo, Qian Li, Kyoungmin Park, Allen C Clermont, Oluwatobi Yerokun, Mark Rekhter, George L King.   

Abstract

OBJECTIVE: To determine the contribution of hyperinsulinemia to atherosclerosis development. METHODS AND
RESULTS: Apolipoprotein E (Apoe) null mice that had knockout of a single allele of the insulin receptor (Insr) gene were compared with littermate Apoe null mice with intact insulin receptors. Plasma insulin levels in Insr haploinsufficient/Apoe null mice were 50% higher in the fasting state and up to 69% higher during a glucose tolerance test, but glucose tolerance was not different in the 2 groups. C-peptide levels, insulin sensitivity, and postreceptor insulin signaling in muscle, liver, fat, and aorta were not different between groups, whereas disappearance in plasma of an injected insulin analog was delayed in Insr haploinsufficient/Apoe null mice, indicating that impaired insulin clearance was the primary cause of hyperinsulinemia. No differences were observed in plasma lipids or blood pressure. Despite the hyperinsulinemia, atherosclerotic lesion size was not different between the 2 groups at time points up to 52 weeks of age when measured as en face lesion area in the aorta, cross-sectional plaque area in the aortic sinus, and cholesterol abundance in the brachiocephalic artery.
CONCLUSIONS: Hyperinsulinemia, without substantial vascular or whole-body insulin resistance and without changes in plasma lipids or blood pressure, does not change susceptibility to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426129      PMCID: PMC3640325          DOI: 10.1161/ATVBAHA.111.239558

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  36 in total

1.  Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice.

Authors:  Christian Rask-Madsen; Qian Li; Bryn Freund; Danielle Feather; Roman Abramov; I-Hsien Wu; Kai Chen; Junko Yamamoto-Hiraoka; Jan Goldenbogen; Konstantinos B Sotiropoulos; Allen Clermont; Pedro Geraldes; Claudia Dall'Osso; Amy J Wagers; Paul L Huang; Mark Rekhter; Rosario Scalia; C Ronald Kahn; George L King
Journal:  Cell Metab       Date:  2010-05-05       Impact factor: 27.287

2.  Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2.

Authors:  Y Kido; D J Burks; D Withers; J C Bruning; C R Kahn; M F White; D Accili
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

3.  Insulin causes endothelial dysfunction in humans: sites and mechanisms.

Authors:  Guido Arcaro; Anna Cretti; Sara Balzano; Alessandro Lechi; Michele Muggeo; Enzo Bonora; Riccardo C Bonadonna
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

4.  Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland.

Authors:  K Pyöräla
Journal:  Diabetes Care       Date:  1979 Mar-Apr       Impact factor: 19.112

5.  Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population.

Authors:  P Ducimetiere; E Eschwege; L Papoz; J L Richard; J R Claude; G Rosselin
Journal:  Diabetologia       Date:  1980-09       Impact factor: 10.122

6.  LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice.

Authors:  Sandra A Schreyer; Cynthia Vick; Theodore C Lystig; Paul Mystkowski; Renée C LeBoeuf
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-01       Impact factor: 4.310

Review 7.  Insulin clearance in obesity.

Authors:  M Elena Valera Mora; Antonino Scarfone; Menotti Calvani; Aldo V Greco; Geltrude Mingrone
Journal:  J Am Coll Nutr       Date:  2003-12       Impact factor: 3.169

8.  A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies.

Authors:  L Andersen; P N Jørgensen; L B Jensen; D Walsh
Journal:  Clin Biochem       Date:  2000-11       Impact factor: 3.281

9.  Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile.

Authors:  Umberto Campia; Gail Sullivan; Melissa B Bryant; Myron A Waclawiw; Michael J Quon; Julio A Panza
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-08-28       Impact factor: 4.733

10.  Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study.

Authors:  Marian Rewers; Daniel Zaccaro; Ralph D'Agostino; Steven Haffner; Mohammed F Saad; Joe V Selby; Richard Bergman; Peter Savage
Journal:  Diabetes Care       Date:  2004-03       Impact factor: 19.112

View more
  18 in total

1.  Glycemic reduction alters white blood cell counts and inflammatory gene expression in diabetes.

Authors:  Xiang Fang; Brenda Dorcely; Xi-Ping Ding; Shi Yin; Ni-Huiping Son; Shi-Lian Hu; Ira J Goldberg
Journal:  J Diabetes Complications       Date:  2018-08-04       Impact factor: 2.852

2.  Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function.

Authors:  Kyoungmin Park; Qian Li; Net Daş Evcimen; Christian Rask-Madsen; Yasutaka Maeda; Ernesto Maddaloni; Hisashi Yokomizo; Takanori Shinjo; Ronald St-Louis; Jialin Fu; Daniel Gordin; Mogher Khamaisi; David Pober; Hillary Keenan; George L King
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-21       Impact factor: 8.311

Review 3.  Insulin resistance: metabolic mechanisms and consequences in the heart.

Authors:  E Dale Abel; Karen M O'Shea; Ravichandran Ramasamy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

Review 4.  Role of insulin action in the pathogenesis of diabetic complications.

Authors:  Kyoichiro Tsuchiya
Journal:  Diabetol Int       Date:  2022-09-07

Review 5.  Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.

Authors:  Agnieszka Przezak; Weronika Bielka; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

Review 6.  Vascular complications of diabetes: mechanisms of injury and protective factors.

Authors:  Christian Rask-Madsen; George L King
Journal:  Cell Metab       Date:  2013-01-08       Impact factor: 27.287

7.  Insulin decreases atherosclerosis by inducing endothelin receptor B expression.

Authors:  Kyoungmin Park; Akira Mima; Qian Li; Christian Rask-Madsen; Pingnian He; Koji Mizutani; Sayaka Katagiri; Yasutaka Maeda; I-Hsien Wu; Mogher Khamaisi; Simone Rordam Preil; Ernesto Maddaloni; Ditte Sørensen; Lars Melholt Rasmussen; Paul L Huang; George L King
Journal:  JCI Insight       Date:  2016-05-05

8.  Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-β isoform in the endothelium.

Authors:  Qian Li; Kyoungmin Park; Chenzhong Li; Christian Rask-Madsen; Akira Mima; Weier Qi; Koji Mizutani; Paul Huang; George L King
Journal:  Circ Res       Date:  2013-06-11       Impact factor: 17.367

9.  Proximal tubular epithelial insulin receptor mediates high-fat diet-induced kidney injury.

Authors:  Hak Joo Lee; Meenalakshmi M Mariappan; Luke Norton; Terry Bakewell; Denis Feliers; Sae Byeol Oh; Andrew Donati; Cherubina S Rubannelsonkumar; Manjeri A Venkatachalam; Stephen E Harris; Isabelle Rubera; Michel Tauc; Goutam Ghosh Choudhury; C Ronald Kahn; Kumar Sharma; Ralph A DeFronzo; Balakuntalam S Kasinath
Journal:  JCI Insight       Date:  2021-02-08

Review 10.  Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?

Authors:  Shawn B Bender; Adam P McGraw; Iris Z Jaffe; James R Sowers
Journal:  Diabetes       Date:  2013-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.